Treatment guidelines in polycythemia vera currently recommend maintaining hematocrit below 45%, with a higher threshold for ...

A panelist discusses how available therapeutic strategies have enhanced their approach to treatment sequencing in patients with polycythemia vera (PV) by providing a broader armamentarium that allows ...

Pint Pharma and PharmaEssentia announced today that ANVISA (Brazilian Health Regulatory Agency) has approved BESREMi® ...

A panelist discusses how recent advancements in molecular diagnostics, targeted therapies, and individualized treatment approaches give them greatest optimism for patients with polycythemia vera (PV) ...

has approved BESREMi® (ropeginterferon alfa-2b) for the treatment of adult patients with Polycythemia Vera (PV).

Identifying the JAK2V617F mutation has improved understanding of what causes overproduction of red blood cells, platelets, ...

Polycythemia Vera (PV) is a rare, chronic, debilitating, and potentially fatal myeloproliferative neoplasm, originating from a disease-initiating stem cell in the bone marrow. This results in a ...

SÃO PAULO--(BUSINESS WIRE)--Pint Pharma and PharmaEssentia announced today that ANVISA (Brazilian Health Regulatory Agency) has approved BESREMi® (ropeginterferon alfa-2b) for the treatment of adult ...

OrthoMinds, LLC ("OrthoMinds") is providing notice of a recent data security event. OrthoMinds is notifying clients and potentially impacted individuals of the event. This notice provides information ...

Secretome Therapeutics, a pioneering company in the field of regenerative medicine, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to STM-01, the ...